Edimer Pharmaceuticals Raises $18 Mln in Series B Financing
Edimer Pharmaceuticals said Tuesday that it has closed $18 million in Series B financing. The lead investor was New Enterprise Associates. New investor Sanofi-Genzyme BioVentures and previous investors Third Rock Ventures and VI Partners also participated in the round. In addition to the news about funding, David Mott will join Edimer's board. Based in Cambridge, Mass., Edimer Pharmaceuticals is a biotech company.
30 July 2013•5 mins read
